TRCT
MIRM icon

Tower Research Capital (TRC)’s Mirum Pharmaceuticals MIRM Stock Holding History

Tower Research Capital (TRC)’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Sell
2,318
-3,322
-59% -$334K 0.01% 1464
2026
Q1 		$521K Buy
5,640
+3,481
+161% +$327K 0.01% 883
2025
Q4 		$171K Buy
2,159
+725
+51% +$52K ﹤0.01% 1557
2025
Q3 		$105K Sell
1,434
-3,354
-70% -$213K ﹤0.01% 1946
2025
Q2 		$244K Buy
4,788
+3,810
+390% +$170K 0.01% 1595
2025
Q1 		$44.1K Sell
978
-4,134
-81% -$195K ﹤0.01% 2314
2024
Q4 		$211K Buy
5,112
+3,694
+261% +$154K ﹤0.01% 1682
2024
Q3 		$55.3K Sell
1,418
-5,779
-80% -$231K ﹤0.01% 2668
2024
Q2 		$246K Buy
7,197
+3,844
+115% +$101K ﹤0.01% 1914
2024
Q1 		$84.2K Sell
3,353
-882
-21% -$24.2K ﹤0.01% 1924
2023
Q4 		$125K Buy
4,235
+2,642
+166% +$80K ﹤0.01% 2466
2023
Q3 		$50.3K Sell
1,593
-253
-14% -$6.93K ﹤0.01% 2543
2023
Q2 		$47.8K Buy
1,846
+1,202
+187% +$32K ﹤0.01% 2620
2023
Q1 		$15K Sell
644
-1,685
-72% -$38.4K ﹤0.01% 3796
2022
Q4 		$45K Buy
2,329
+119
+5% +$2.35K ﹤0.01% 2433
2022
Q3 		$46K Sell
2,210
-593
-21% -$14.3K ﹤0.01% 3237
2022
Q2 		$55K Sell
2,803
-2,876
-51% -$67.8K ﹤0.01% 2798
2022
Q1 		$125K Buy
5,679
+1,611
+40% +$32.9K ﹤0.01% 2048
2021
Q4 		$65K Buy
4,068
+3,486
+599% +$54.2K ﹤0.01% 2559
2021
Q3 		$12K Sell
582
-63
-10% -$1.02K ﹤0.01% 4158
2021
Q2 		$11K Buy
645
+8
+1% +$143 ﹤0.01% 4329
2021
Q1 		$13K Sell
637
-4,920
-89% -$94.2K ﹤0.01% 4207
2020
Q4 		$97K Sell
5,557
-979
-15% -$19.2K ﹤0.01% 2383
2020
Q3 		$126K Buy
6,536
+5,376
+463% +$115K ﹤0.01% 2954
2020
Q2 		$23K Buy
+1,160
New +$19.4K ﹤0.01% 3605
2019
Q4 		– Sell
-886
Closed -$9K – 4057
2019
Q3 		$9K Buy
+886
New +$10.9K ﹤0.01% 3001

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s MIRM Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Mirum Pharmaceuticals (MIRM) stake by 59% in Q2 2026, selling an estimated $334K and leaving 2,318 shares worth $271K. The position accounts for 0.01% of the portfolio, ranked #1464.

Tower Research Capital (TRC) first reported a position in MIRM in Q3 2019 and has held it in 26 quarters since. The position peaked at $521K in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Tower Research Capital (TRC) held 2,318 shares of Mirum Pharmaceuticals worth $271K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,322 Mirum Pharmaceuticals shares in Q2 2026, an estimated $334K.
  • Mirum Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1464 holding.
  • Tower Research Capital (TRC) first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Mirum Pharmaceuticals position peaked at $521K in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.